Beam Therapeutics (BEAM) Shares Outstanding (2019 - 2026)

Beam Therapeutics (BEAM) has reported Shares Outstanding (Entity) for 8 consecutive years, with $102.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 2.17% year-over-year to $102.7 million; the TTM figure through Mar 2026 stood at $102.7 million (up 2.17% YoY), while the FY2025 annual figure was $101.7 million, up 21.66% from the prior year.
• Shares Outstanding (Entity) advanced to $102.7 million in Q1 2026 per BEAM's latest filing, from $101.7 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $102.7 million in Q1 2026 and bottomed at $69.8 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $84.3 million across 5 years, with a median of $82.3 million in 2024.
• Annual changes were most pronounced in 2025 — Shares Outstanding (Entity) grew 22.77% — and 2026, when it grew 2.17%.
• Beam Therapeutics' Shares Outstanding (Entity) stood at $71.3 million in 2022, then climbed by 14.53% to $81.6 million in 2023, then advanced by 2.45% to $83.6 million in 2024, then grew by 21.66% to $101.7 million in 2025, then rose by 0.98% to $102.7 million in 2026.
• Business Quant data shows BEAM's Shares Outstanding (Entity) at $102.7 million in Q1 2026, $101.7 million in Q4 2025, and $101.4 million in Q3 2025.